#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Biosimilar Drugs in Oncology

8 of the 10 most expensive drugs on the market are used in the treatment of cancer. Rising healthcare costs in recent decades have created a need to find strategies to limit these costs. Biosimilar preparations have the potential to partially replace existing original biological drugs and reduce the cost of cancer treatment. We therefore briefly summarize the basic information on the issue of biosimilars in terms of their benefits, safety, and interchangeability.
Source: Oncological Treatment 22. 11. 2021

News Beta-blockers in the treatment of chronic heart failure: How did the analysis of the effects of 4 drugs in 26 studies turn out?

As a cornerstone of therapy for chronic heart failure with reduced ejection fraction (HFrEF), it is recommended to start treatment with a very low dose of beta-blockers (BB) and titrate it to the maximum tolerated dose. However, it remains unclear whether one BB is superior to others. For this reason, a comprehensive pooled analysis of the efficacy and safety of bisoprolol, carvedilol, nebivolol, and metoprolol in 26 studies, including 14 randomized controlled and 12 observational, was recently published.
Source: Cardiovascular Continuum 28. 3. 2023

News Impact of Early Administration of High Protein Dose on Mortality of Critically Ill Patients

Energy intake and the composition of individual macronutrients in patients in intensive care units (ICUs) can influence treatment outcomes in terms of the incidence of complications, duration of mechanical ventilation, or mortality.
Source: Parenteral Nutrition 14. 11. 2022

News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients

Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.
Source: Psoriasis 3. 6. 2022

Journal articles Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?

Author of the article: Martina Vašáková Source: Vnitřní lékařství | 11/2017 2. 1. 2018

News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS −⁠ What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?

Current treatment options for irritable bowel syndrome (IBS −⁠ irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.
Source: Irritable Bowel Syndrome 12. 11. 2022

News MUDr. Petra Garnolová: The combination of medical cannabis with other analgesics is the ideal way to achieve the best effect with the fewest side effects

Medical cannabis is gradually finding its way to many patients with various ailments, including those with unmanageable and hard-to-influence chronic pain. For them, this therapy can offer a new chance at a quality life despite severe or terminal illness. A relatively new form that brings additional benefits is the extract of medical cannabis. We spoke with MUDr. Petra Garnolová, a specialist in clinical oncology and palliative medicine, about why it is worth considering not only as part of analgesic therapy and her experiences from real practice.
Source: Medical Cannabis 8. 1. 2024

News Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol

A newly published study by authors from Singapore focused on the ability of the SEP protocol –⁠ short-term low-dose enoxaparin administration based on body weight –⁠ to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.
Source: Thromboprophylaxis 3. 1. 2024

Journal articles RADICAL SURGICAL TREATMENT OF HIDRADENITIS SUPPURATIVA OF PENIS AND SCROTUM

Author of the article: Milan Hora, Michal Sviták, Vlastimil Bursa, Petr Stránský, Viktor Eret, Tomáš Ürge, Ondřej Hes, Denisa Kacerovská, Karel Pizinger Source: Česká urologie | 4/2011 14. 11. 2011

News Through Obstacles to the Stars –⁠ Path to Developing a Healthy Gut Microbiota in Children: What Blocks It and What Helps?

The gut microbiota is acquired by an individual during the first 2 years of life. The main source is the mother’s microbiota. Obstacles to the formation of an adequate microbiota include inappropriate composition of the mother’s microbiota, absence of vaginal birth and breastfeeding, as well as artificial feeding and antibiotic treatment in the child. We provide a summary of current findings on the adverse effects of planned cesarean sections on the child’s microbiome, as recently published in Critical Reviews in Microbiology.
Source: GI, colic and microbiome 21. 4. 2020

News Human Papillomavirus in Adults –⁠ HPV Does Not Choose Gender

A significant part of the population is exposed to human papillomaviruses (HPV) throughout their lives. In recent years, there has been a global effort to increase vaccination coverage not only among children and adolescents who have not yet been vaccinated but also among adult women and men who could benefit from it, including those who have likely already encountered HPV.
Source: Regular Vaccination 31. 5. 2024

News Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF

The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant von Willebrand factor (rvWF) in 23 patients with severe von Willebrand disease (vWD), who had previously been treated either on-demand (during spontaneous bleeding episodes) or had been on prophylaxis with plasma-derived vWF (pdvWF).
Source: Hemophilia 4. 11. 2024

News Options of Anticoagulant Therapy During Pregnancy: Focus on Fondaparinux

The use of most medicinal products is limited during pregnancy either by known teratogenic effects or by lack of safety data for the mother and fetus. A systematic review by authors from the University of Liverpool provides information on the options for anticoagulant treatment during pregnancy.
Source: Management of Thrombosis in Women 24. 3. 2020

News Gene Therapy for Hemophilia A: What is the Expression of Factor VIII Using the Adeno-Associated Viral Vector SPK-8011?

The goal of gene therapy for hemophilia A is to safely transfer stable and durable expression of coagulation factor VIII (FVIII), which predictably improves the bleeding phenotype at the lowest possible vector dose. Updated data from a study examining the use of the adeno-associated viral vector (AAV) SPK-8011 were presented during the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH) 2021.
Source: Quality Life Even with Hemophilia 24. 11. 2021

News Use of Bilastine in Pediatrics −⁠ Pathway to Improving Concentration and Performance of Young Allergy Sufferers

In the treatment of allergic diseases, especially in children, safety, good tolerability, simple dosing regimen, and non-sedative effects are the basic requirements for administered medications. Sedative side effects of treatment have a negative impact on sleep patterns and subsequently on children's performance in school. European professional societies recommend the use of modern second-generation antihistamines in the treatment of children. Studies confirm that bilastine, which meets these requirements, should be among the first-choice drugs.
Source: Allergic Reactions 1. 10. 2020

News 48 Tablets of Teriflunomide? Nothing Should Be Overdone! −⁠ Case Study

A case study published in the Journal of Clinical Pharmacy and Therapeutics describes an overdose of teriflunomide, specifically the ingestion of 672 mg of this drug. What measures did the doctors take with the patient? And were they able to prevent serious consequences?
Source: Multiple Sclerosis 15. 8. 2023

News Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension

Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor, is a widely used antihypertensive. The PPAR-γ receptor plays a role in the genesis of osteoblasts and osteoclasts, and antidiabetic drugs from the thiazolidinedione group, which act as agonists of this receptor, have a known inhibitory effect on bone metabolism and increase the risk of non-traumatic fractures. Knowledge regarding the potential similar effects of telmisartan is limited. The following study compared the effects of telmisartan and losartan (an AT1 blocker without agonistic effect on PPAR-γ) on bone turnover markers in patients with newly diagnosed hypertension.
Source: Sartans in the Treatment of Hypertension 12. 8. 2021

News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy

The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.
Source: Arthritis 8. 6. 2023

Journal articles Chronic lymphocytic leukaemia –⁠ contemporary application of modern prognostic and predictive markers  in diagnostics

Author of the article: Š. Pospíšilová, M. Jarošová, M. Doubek Source: Transfuze a hematologie dnes | 1/2019 29. 3. 2019

News Patient with generalized malignant melanoma treated with nivolumab in the first line

A 75-year-old patient was referred for examination at the dermato-oncology clinic of the Dermatology Clinic of VFN in September 2016. He was being treated for ICHS and had undergone prostate surgery for hyperplasia in 2013.
Source: Case Studies from Immunooncology 10. 9. 2020

News Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors

Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed the treatment approach and brought patients prolonged progression-free survival or even overall survival. It has become a standard of care for many advanced cancers. What do we know today about this monoclonal antibody, first introduced in routine practice in 2005?
Source: Oncological Treatment 19. 8. 2022

News Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor

The current publication of the long-term extension of the UNCOVER-3 study, which focused on the treatment of psoriasis with ixekizumab, describes the efficacy and safety of 4 years of use of this drug.
Source: Biological Treatment 13. 4. 2021

News Effectiveness of Arginine in Tooth Cleaning Proven (Not Only) by Quantitative Light-Induced Fluorescence

There is no doubt about the benefits of toothpaste in daily dental care. Today, there are numerous studies proving that brushing without toothpaste does not have the same effectiveness as brushing with toothpaste. It is more effective and, thanks to active ingredients, can slow down or even reverse the development of tooth decay.
Source: Dental Caries 4. 5. 2020

News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy

The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Source: Treatment of Asthma and COPD 15. 7. 2020

News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate

The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.
Source: Biological Treatment 17. 2. 2020

1 32 33 34 35 36 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#